



Monovisc: 4 mL one time  
 Orthovisc: 2 mL weekly for 3 to 4 weeks  
 Supartz FX: 2.5 mL weekly for 3 to 5 weeks  
 Synvisc: 2 mL weekly for 3 weeks  
 Synvisc-One: 6 mL one time  
 TriVisc: 2.5 mL weekly for 3 weeks  
 TriLuron: 2 mL weekly for 3 weeks  
 Visco-3: 2.5 mL weekly for 3 weeks

***If all the above requirements are met, the medication will be approved for 6 months.***

For **reauthorization**:

1. Chart notes must show clinically significant improvement of signs and symptoms such as documentation of improved pain scores, improved functional abilities, and/or reduced use of analgesic medications as a result of the treatment to the affected knee; AND
2. Symptoms have recurred and at least 6 months have elapsed since completion of the previous course of viscosupplementation; AND
3. Member has not had a total knee replacement (arthroplasty) and knee replacement is not anticipated for at least the next 6 months.

***If all the above requirements are met, the medication will be approved for an additional 6 months.***

**CareSource considers hyaluronic acid viscosupplements not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.**

DATE	ACTION/DESCRIPTION
04/20/2022	New policy for hyaluron

1. Euflexxa [package insert]. Ferring Pharmaceuticals, Inc.; 2016.
2. Durolane [package insert]. Bioventus LLC; 2017.
3. Gel-One [package insert]. Zimmer, Inc.; 2011.
4. Gelsyn-3 [package insert]. Bioventus; 2017.
5. GenVisc 850 [package insert]. OrthogenRx. N.D.
6. Hyalgan [package insert]. Fidia Pharma USA Inc.; 2014.
7. Hymovis [package insert]. Fidia Pharma USA Inc.; 2017.
8. Monovisc [package insert]. Anika Therapeutics Inc.; 2013.
9. Orthovisc [package insert]. Anika Therapeutics. N.d.
10. Supartz FX [package insert]. Bioventus LLC; 2015
11. Synvisc [package insert]. Genzyme Biosurgery; 2014.
12. Synvisc-One [package insert]. Genzyme Biosurgery; 2014.
13. TriVisc. [package insert]. OrthogenRx, Inc.
14. TriLuron. [package insert]. Fidia Pharma USA Inc.; 2019.
15. Visco-3. [package insert]. Bioventus LLC.
16. American Academy of Orthopaedic Surgeons Management of Osteoarthritis of the Knee (NonArthroplasty) Evidence-Based Clinical Practice Guideline. <https://www.aaos.org/oak3cpg> Published 08/31/2021
17. Uson J, Rodriguez-García SC, Castellanos-Moreira R, et al. EULAR recommendations for intra-articular therapies. *Ann Rheum Dis*. BDC /5 (c)-2 0.5 (R)-1.5 (he)6.1 (um)7.7 ( )0.nr5 (nt)3 Pharma (r)-1(e)TJ0:.904 0 2 29 (c)-1.9 (